Aardvark Therapeutics, Inc. Common Stock (AARD)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 28
- Market Cap
- $126M
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
SentiSense also tracks daily options readings for Aardvark Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Aardvark Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.